Evolutionary strategy for systemic therapy of metastatic breast cancer: Balancing response with suppression of resistance

Women's Health

Volumn 10, Issue 4, 2014, Pages 423-430

  Kam, Yoonseok ^a   Das, Tuhin ^a   Minton, Susan ^a   Gatenby, Robert A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

adaptive therapy; breast cancer; chemotherapy; double bind therapy; drug resistance; estrogen; hormonal therapy; tumor evolution

Indexed keywords

ADAPTIVE THERAPY; BREAST METASTASIS; CANCER CELL; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CELL HETEROGENEITY; CELL PROLIFERATION; DOUBLE BIND THERAPY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; REVIEW; SYSTEMIC THERAPY; TREATMENT FAILURE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADENOSINE TRIPHOSPHATE; ANIMALS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PHENOTYPE; RECEPTOR, ERBB-2; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 84907479178     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.23     Document Type: Review

References (36)

1. Hudis CA. Trastuzumab -mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007).
2. Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J. Clin. Oncol. 18(10), 2059-2069 (2000).
3. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 69(4), 1243-1254 (2009).
4. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 134(6), 907-922 (2010).
5. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
6. Aktipis CA, Kwan VS, Johnson KA, Neuberg SL, Maley CC. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLoS ONE 6(11), e26100 (2011).
7. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 72(24), 6362-6370 (2012).
8. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103(8), 1139-1143 (2010).
9. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
10. Hsiao YH, Chou MC, Fowler C, Mason JT, Man YG. Breast cancer heterogeneity: mechanisms, proofs, and implications. Cancer 1, 6-13 (2010).
11. Wishart GC, Plumb JA, Going JJ, et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br. J. Cancer 62(5), 758-761 (1990).
12. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1), 77-88 (2010).
13. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002).
14. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13(4), e178-e185 (2012).
15. Gaynor ER, Unger JM, Miller TP, et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J. Clin. Oncol. 19, 750-755 (2001).
16. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 69(11), 4894-4903 (2009).
17. Wind NS, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int. J. Breast Cancer 2011, 967419 (2011).
18. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 10(2), 147-156 (2010).
19. Broxterman HJ, Pinedo HM, Kuiper CM, Kaptein LC, Schuurhuis GJ, Lankelma J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J. 2(7), 2278-2282 (1988).
20. Broxterman HJ, Pinedo HM, Kuiper CM, Schuurhuis GJ, Lankelma J. Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents. FEBS Lett. 247(2), 405-410 (1989).
21. Millon SR, Ostrander JH, Brown JQ, Raheja A, Seewaldt VL, Ramanujam N. Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. Breast Cancer Res. Treat. 126(1), 55-62 (2011).
22. Cunningham JJ, Gatenby RA, Brown JS. Evolutionary dynamics in cancer therapy. Mol. Pharm. 8(6), 2094-2100 (2011).
23. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12(3 Pt 1), 878-887 (2006).
24. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354(3), 270-282 (2006).
25. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol. 9, 2584-2589 (1996).
26. Aguilar H, Sole X, Bonifaci N, et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 29(45), 6071-6083 (2010).
27. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 120(7), 2406-2413 (2010).
28. Fox EM, Miller TW, Balko JM, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 71(21), 6773-6784 (2011).
29. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 11(4), 623-641 (2004).
30. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 81(4-5), 333-341 (2002).
31. Santen RJ, Song RX, Zhang Z, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 12(Suppl. 1), S61-S73 (2005).
32. Mahtani RL, Stein A, Vogel CL. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. Clin. Ther. 31, 2371-2378 (2009).
33. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res. 4(4), 133-136 (2002).
34. Osipo C, Gajdos C, Cheng D, Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Steroid Biochem. Mol. Biol. 93(2-5), 249-256 (2005).
35. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 11(3), 206 (2009).
36. Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin. Breast Cancer 8(2), 124-133 (2008).